{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-24-000037","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.366536+00:00","generated_at":"2026-05-30T02:53:56.313252+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance","bullets":["Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.","GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.","Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.","Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.","Affirms full-year 2024 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-24-000037","json":"https://secwatch.observer/filing/0001723128-24-000037.json","markdown":"https://secwatch.observer/filing/0001723128-24-000037.md","text":"https://secwatch.observer/filing/0001723128-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/0001723128-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/amrx-q32024x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:53:56.313252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}